Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Cara Therapeutics Company Profile (NASDAQ:CARA)

Consensus Ratings for Cara Therapeutics (NASDAQ:CARA) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.00 (111.95% upside)

Analysts' Ratings History for Cara Therapeutics (NASDAQ:CARA)
Show:
DateFirmActionRatingPrice TargetDetailsShare
3/3/2015MLV & Co Initiated CoverageBuy$26.00ViewTweet This Rating  Share This Rating on StockTwits
1/9/2015Canaccord GenuityInitiated CoverageBuy$20.00ViewTweet This Rating  Share This Rating on StockTwits
12/9/2014Summer StreetInitiated CoverageBuy$20.00ViewTweet This Rating  Share This Rating on StockTwits
5/15/2014Canaccord GenuityBoost Price Target$25.00 -> $29.00ViewTweet This Rating  Share This Rating on StockTwits
2/27/2014Needham & Company LLCInitiated CoverageBuy$27.00ViewTweet This Rating  Share This Rating on StockTwits
2/25/2014Stifel NicolausInitiated CoverageBuy$21.00ViewTweet This Rating  Share This Rating on StockTwits
2/25/2014Canaccord GenuityInitiated CoverageBuy -> Buy$25.00ViewTweet This Rating  Share This Rating on StockTwits
2/25/2014Janney Montgomery ScottInitiated CoverageBuyViewTweet This Rating  Share This Rating on StockTwits
2/25/2014Piper JaffrayInitiated CoverageOverweight$23.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 3/5/2013 forward)